Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary EndpointGlobeNewsWire • 10/30/26
Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's ReadoutSeeking Alpha • 10/28/26
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business HighlightsGlobeNewsWire • 10/26/26
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewsWire • 10/22/26
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026GlobeNewsWire • 10/19/26
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/10/26
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business HighlightsGlobeNewsWire • 08/12/26
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026GlobeNewsWire • 08/05/26
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 07/31/26
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to BuyZacks Investment Research • 07/15/26
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?Zacks Investment Research • 07/15/26
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026GlobeNewsWire • 07/15/26
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026GlobeNewsWire • 07/07/26
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology PlatformBusiness Wire • 06/17/26
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 06/16/26